ELN Recommendations | CML Alliance
For Healthcare Professionals Outside the US
Send To a FriendPrint This PageChange Text Size

ELN RecommendationsELN Recommendations

Leading guidelines now recommend molecular monitoring as a standard of care for patients with Ph+ CML.1,2

Both the ELN and the National Comprehensive Cancer Network (NCCN) recommend molecular monitoring every 3 months.1,2 Table 1 below identifies the new optimal treatment goals as recommended by the ELN.


Please click on the image to enlarge it



Next: Monitoring Treatment Response


Note: Before prescribing, please read full European Summary of Product Characteristics.

References

  1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
  2. The NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 2.2011). ©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed November 2, 2010. To view the most recent and complete version of the guidelines, go online to www.nccn.org.